{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:44:01Z","timestamp":1794998641512,"version":"4.9.1"},"reference-count":218,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41582-018-0051-6","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T06:36:07Z","timestamp":1534833367000},"page":"590-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":243,"title":["Spinocerebellar ataxias: prospects and challenges for therapy development"],"prefix":"10.1038","volume":"14","author":[{"given":"Tetsuo","family":"Ashizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclin","family":"\u00d6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry L.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"51_CR1","unstructured":"Bird, T. D. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, Seattle, 1998, last updated 2016)."},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrn.2017.92","volume":"18","author":"HL Paulson","year":"2017","unstructured":"Paulson, H. L., Shakkottai, V. G., Clark, H. B. & Orr, H. T. Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat. Rev. Neurosci. 18, 613\u2013626 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12311-008-0023-2","volume":"7","author":"T Klockgether","year":"2008","unstructured":"Klockgether, T. The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum 7, 101\u2013105 (2008).","journal-title":"Cerebellum"},{"key":"51_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/14734220510007914","volume":"4","author":"MU Manto","year":"2005","unstructured":"Manto, M. U. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 4, 2\u20136 (2005).","journal-title":"Cerebellum"},{"key":"51_CR5","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000004311","volume":"89","author":"I Giordano","year":"2017","unstructured":"Giordano, I. et al. Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology 89, 1043\u20131049 (2017).","journal-title":"Neurology"},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ene.12341","volume":"21","author":"BP Warrenburg van de","year":"2014","unstructured":"van de Warrenburg, B. P. et al. EFNS\/ENS consensus on the diagnosis and management of chronic ataxias in adulthood. Eur. J. Neurol. 21, 552\u2013562 (2014).","journal-title":"Eur. J. Neurol."},{"key":"51_CR7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003648","volume":"9","author":"RP Menon","year":"2013","unstructured":"Menon, R. P. et al. The role of interruptions in polyQ in the pathology of SCA1. PLoS Genet. 9, e1003648 (2013).","journal-title":"PLoS Genet."},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1212\/01.wnl.0000269323.21969.db","volume":"69","author":"P Charles","year":"2007","unstructured":"Charles, P. et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology 69, 1970\u20131975 (2007).","journal-title":"Neurology"},{"key":"51_CR9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175958","volume":"12","author":"I Landrian","year":"2017","unstructured":"Landrian, I. et al. Inheritance patterns of ATCCT repeat interruptions in spinocerebellar ataxia type 10 (SCA10) expansions. PLoS ONE 12, e0175958 (2017).","journal-title":"PLoS ONE"},{"key":"51_CR10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135906","volume":"10","author":"KN McFarland","year":"2015","unstructured":"McFarland, K. N. et al. SMRT sequencing of long tandem nucleotide repeats in SCA10 reveals unique insight of repeat expansion structure. PLoS ONE 10, e0135906 (2015).","journal-title":"PLoS ONE"},{"key":"51_CR11","unstructured":"Opal, P. & Ashizawa, T. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, Seattle, 1997, last updated 2017)."},{"key":"51_CR12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.parkreldis.2008.09.005","volume":"15","author":"MP Socal","year":"2009","unstructured":"Socal, M. P. et al. Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat. Disord. 15, 374\u2013378 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"51_CR13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/mds.21228","volume":"22","author":"A Modoni","year":"2007","unstructured":"Modoni, A. et al. Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients. Mov. Disord. 22, 324\u2013327 (2007).","journal-title":"Mov. Disord."},{"key":"51_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41531-017-0029-x","volume":"3","author":"B Schule","year":"2017","unstructured":"Schule, B. et al. Parkinson\u2019s disease associated with pure ATXN10 repeat expansion. NPJ Parkinsons Dis. 3, 27 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"51_CR15","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-015-0425-y","volume":"15","author":"L Choubtum","year":"2015","unstructured":"Choubtum, L. et al. Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study. BMC Neurol. 15, 166 (2015).","journal-title":"BMC Neurol."},{"key":"51_CR16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0009-9163.2004.00213.x","volume":"65","author":"YR Wu","year":"2004","unstructured":"Wu, Y. R. et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson\u2019s disease. Clin. Genet. 65, 209\u2013214 (2004).","journal-title":"Clin. Genet."},{"key":"51_CR17","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1093\/hmg\/ddr227","volume":"20","author":"OA Ross","year":"2011","unstructured":"Ross, O. A. et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 20, 3207\u20133212 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","volume":"466","author":"AC Elden","year":"2010","unstructured":"Elden, A. C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069\u20131075 (2010).","journal-title":"Nature"},{"key":"51_CR19","volume":"6","author":"Z Yu","year":"2011","unstructured":"Yu, Z. et al. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS ONE 6, e17951 (2011).","journal-title":"PLoS ONE"},{"key":"51_CR20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10048-013-0385-6","volume":"15","author":"KN McFarland","year":"2014","unstructured":"McFarland, K. N. et al. Repeat interruptions in spinocerebellar ataxia type 10 expansions are strongly associated with epileptic seizures. Neurogenetics 15, 59\u201364 (2014).","journal-title":"Neurogenetics"},{"key":"51_CR21","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/brain\/awx251","volume":"140","author":"EAR Nibbeling","year":"2017","unstructured":"Nibbeling, E. A. R. et al. Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia. Brain 140, 2860\u20132878 (2017).","journal-title":"Brain"},{"key":"51_CR22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nnano.2009.12","volume":"4","author":"J Clarke","year":"2009","unstructured":"Clarke, J. et al. Continuous base identification for single-molecule nanopore DNA sequencing. Nat. Nanotechnol. 4, 265\u2013270 (2009).","journal-title":"Nat. Nanotechnol."},{"key":"51_CR23","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2013-14-6-405","volume":"14","author":"RJ Roberts","year":"2013","unstructured":"Roberts, R. J., Carneiro, M. O. & Schatz, M. C. The advantages of SMRT sequencing. Genome Biol. 14, 405 (2013).","journal-title":"Genome Biol."},{"key":"51_CR24","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0b013e3181c33adf","volume":"73","author":"W Ilg","year":"2009","unstructured":"Ilg, W. et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73, 1823\u20131830 (2009).","journal-title":"Neurology"},{"key":"51_CR25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","volume":"13","author":"W Ilg","year":"2014","unstructured":"Ilg, W. et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13, 248\u2013268 (2014).","journal-title":"Cerebellum"},{"key":"51_CR26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1545968311425918","volume":"26","author":"I Miyai","year":"2012","unstructured":"Miyai, I. et al. Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil. Neural Repair 26, 515\u2013522 (2012).","journal-title":"Neurorehabil. Neural Repair"},{"key":"51_CR27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1590\/S0100-879X2010005000009","volume":"43","author":"RC Silva","year":"2010","unstructured":"Silva, R. C. et al. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz. J. Med. Biol. Res. 43, 537\u2013542 (2010).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"51_CR28","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1212\/WNL.0b013e3182749e67","volume":"79","author":"W Ilg","year":"2012","unstructured":"Ilg, W. et al. Video game-based coordinative training improves ataxia in children with degenerative ataxia. Neurology 79, 2056\u20132060 (2012).","journal-title":"Neurology"},{"key":"51_CR29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.gaitpost.2014.04.190","volume":"40","author":"EM Fonteyn","year":"2014","unstructured":"Fonteyn, E. M. et al. Gait adaptability training improves obstacle avoidance and dynamic stability in patients with cerebellar degeneration. Gait Posture 40, 247\u2013251 (2014).","journal-title":"Gait Posture"},{"key":"51_CR30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.apmr.2015.01.021","volume":"96","author":"YJ Chang","year":"2015","unstructured":"Chang, Y. J. et al. Cycling regimen induces spinal circuitry plasticity and improves leg muscle coordination in individuals with spinocerebellar ataxia. Arch. Phys. Med. Rehabil. 96, 1006\u20131013 (2015).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"51_CR31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00415-013-6910-6","volume":"261","author":"EM Fonteyn","year":"2014","unstructured":"Fonteyn, E. M. et al. The effectiveness of allied health care in patients with ataxia: a systematic review. J. Neurol. 261, 251\u2013258 (2014).","journal-title":"J. Neurol."},{"key":"51_CR32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1179\/016164105X39897","volume":"27","author":"Y Ihara","year":"2005","unstructured":"Ihara, Y., Takata, H., Tanabe, Y., Nobukuni, K. & Hayabara, T. Influence of repetitive transcranial magnetic stimulation on disease severity and oxidative stress markers in the cerebrospinal fluid of patients with spinocerebellar degeneration. Neurol. Res. 27, 310\u2013313 (2005).","journal-title":"Neurol. Res."},{"key":"51_CR33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jnnp.72.1.124","volume":"72","author":"Y Shiga","year":"2002","unstructured":"Shiga, Y. et al. Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. J. Neurol. Neurosurg. Psychiatry 72, 124\u2013126 (2002).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"51_CR34","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.2978-04.2004","volume":"24","author":"T Zu","year":"2004","unstructured":"Zu, T. et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24, 8853\u20138861 (2004).","journal-title":"J. Neurosci."},{"key":"51_CR35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/hmg\/dds495","volume":"22","author":"SA Furrer","year":"2013","unstructured":"Furrer, S. A. et al. Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7. Hum. Mol. Genet. 22, 890\u2013903 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101, 57\u201366 (2000).","journal-title":"Cell"},{"key":"51_CR37","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1523\/JNEUROSCI.3032-06.2006","volume":"26","author":"M Katsuno","year":"2006","unstructured":"Katsuno, M. et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J.\u00a0Neurosci. 26, 12106\u201312117 (2006).","journal-title":"J. Neurosci."},{"key":"51_CR38","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1093\/hmg\/ddw242","volume":"25","author":"I Sanchez","year":"2016","unstructured":"Sanchez, I., Balague, E. & Matilla-Duenas, A. Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3beta-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1). Hum.\u00a0Mol. Genet. 25, 4021\u20134040 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR39","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2006.03.032","volume":"125","author":"J Lim","year":"2006","unstructured":"Lim, J. et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 125, 801\u2013814 (2006).","journal-title":"Cell"},{"key":"51_CR40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001021","volume":"6","author":"J Crespo-Barreto","year":"2010","unstructured":"Crespo-Barreto, J., Fryer, J. D., Shaw, C. A., Orr, H. T. & Zoghbi, H. Y. Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet. 6, e1001021 (2010).","journal-title":"PLoS Genet."},{"key":"51_CR41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12311-008-0009-0","volume":"7","author":"A Matilla-Duenas","year":"2008","unstructured":"Matilla-Duenas, A., Goold, R. & Giunti, P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum 7, 106\u2013114 (2008).","journal-title":"Cerebellum"},{"key":"51_CR42","doi-asserted-by":"crossref","first-page":"41452","DOI":"10.1074\/jbc.M303354200","volume":"278","author":"A Busch","year":"2003","unstructured":"Busch, A. et al. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington\u2019s disease. J. Biol. Chem. 278, 41452\u201341461 (2003).","journal-title":"J. Biol. Chem."},{"key":"51_CR43","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0166-2236(00)01721-5","volume":"24","author":"E Cattaneo","year":"2001","unstructured":"Cattaneo, E. et al. Loss of normal huntingtin function: new developments in Huntington\u2019s disease research. Trends Neurosci. 24, 182\u2013188 (2001).","journal-title":"Trends Neurosci."},{"key":"51_CR44","first-page":"1513","volume":"49","author":"MM Evers","year":"2014","unstructured":"Evers, M. M., Toonen, L. J. & van Roon-Mom, W. M. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. Mol. Neurobiol. 49, 1513\u20131531 (2014).","journal-title":"Mol. Neurobiol."},{"key":"51_CR45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12311-012-0447-6","volume":"12","author":"H Tsoi","year":"2013","unstructured":"Tsoi, H. & Chan, H. Y. Expression of expanded CAG transcripts triggers nucleolar stress in Huntington\u2019s disease. Cerebellum 12, 310\u2013312 (2013).","journal-title":"Cerebellum"},{"key":"51_CR46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-62703-438-8_13","volume":"1017","author":"SE Samaraweera","year":"2013","unstructured":"Samaraweera, S. E. et al. Modeling and analysis of repeat RNA toxicity in Drosophila. Methods Mol. Biol. 1017, 173\u2013192 (2013).","journal-title":"Methods Mol. Biol."},{"key":"51_CR47","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1093\/hmg\/ddr420","volume":"20","author":"SY Shieh","year":"2011","unstructured":"Shieh, S. Y. & Bonini, N. M. Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila. Hum. Mol. Genet. 20, 4810\u20134821 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/nature06909","volume":"453","author":"LB Li","year":"2008","unstructured":"Li, L. B., Yu, Z., Teng, X. & Bonini, N. M. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 453, 1107\u20131111 (2008).","journal-title":"Nature"},{"key":"51_CR49","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ng1827","volume":"38","author":"ML Moseley","year":"2006","unstructured":"Moseley, M. L. et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38, 758\u2013769 (2006).","journal-title":"Nat. Genet."},{"key":"51_CR50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12311-008-0010-7","volume":"7","author":"Y Ikeda","year":"2008","unstructured":"Ikeda, Y., Daughters, R. S. & Ranum, L. P. Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes. Cerebellum 7, 150\u2013158 (2008).","journal-title":"Cerebellum"},{"key":"51_CR51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.24761","volume":"80","author":"PP Li","year":"2016","unstructured":"Li, P. P. et al. ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis. Ann. Neurol. 80, 600\u2013615 (2016).","journal-title":"Ann. Neurol."},{"key":"51_CR52","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.neuron.2011.05.027","volume":"70","author":"BL Sopher","year":"2011","unstructured":"Sopher, B. L. et al. CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron 70, 1071\u20131084 (2011).","journal-title":"Neuron"},{"key":"51_CR53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1073\/pnas.1013343108","volume":"108","author":"T Zu","year":"2011","unstructured":"Zu, T. et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA 108, 260\u2013265 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51_CR54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuron.2017.02.046","volume":"94","author":"T Ishiguro","year":"2017","unstructured":"Ishiguro, T. et al. Regulatory role of RNA chaperone TDP-43 for RNA misfolding and repeat-associated translation in sCA31. Neuron 94, 108\u2013124 e7 (2017).","journal-title":"Neuron"},{"key":"51_CR55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuron.2016.12.016","volume":"93","author":"C Sellier","year":"2017","unstructured":"Sellier, C. et al. Translation of expanded CGG repeats into FMRpolyG is pathogenic and may contribute to fragile X tremor ataxia syndrome. Neuron 93, 331\u2013347 (2017).","journal-title":"Neuron"},{"key":"51_CR56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ana.24800","volume":"80","author":"A Krans","year":"2016","unstructured":"Krans, A., Kearse, M. G. & Todd, P. K. Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor\/ataxia syndrome. Ann. Neurol. 80, 871\u2013881 (2016).","journal-title":"Ann. Neurol."},{"key":"51_CR57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128769","volume":"10","author":"DR Scoles","year":"2015","unstructured":"Scoles, D. R. et al. Repeat associated non-AUG translation (RAN translation) dependent on sequence downstream of the ATXN2 CAG repeat. PLoS ONE 10, e0128769 (2015).","journal-title":"PLoS ONE"},{"key":"51_CR58","volume-title":"Genetic Instabilities and Neurological Disorders","author":"T Ashizawa","year":"2006","unstructured":"Ashizawa, T. & Wells, R. D. Genetic Instabilities and Neurological Disorders (Elsevier, Burlington, 2006)."},{"key":"51_CR59","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nsmb.3486","volume":"24","author":"S Stella","year":"2017","unstructured":"Stella, S., Alcon, P. & Montoya, G. Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss Army knives of genome editing. Nat. Struct. Mol. Biol. 24, 882\u2013892 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"51_CR60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2017.09.007","volume":"68","author":"K Murugan","year":"2017","unstructured":"Murugan, K., Babu, K., Sundaresan, R., Rajan, R. & Sashital, D. G. The revolution continues: newly discovered systems expand the CRISPR-Cas toolkit. Mol. Cell 68, 15\u201325 (2017).","journal-title":"Mol. Cell"},{"key":"51_CR61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys, A. M., Ebanks, S. A., Keiser, M. S. & Davidson, B. L. CRISPR\/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Mol. Ther. 25, 12\u201323 (2017).","journal-title":"Mol. Ther."},{"key":"51_CR62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.4313","volume":"23","author":"TI Cornu","year":"2017","unstructured":"Cornu, T. I., Mussolino, C. & Cathomen, T. Refining strategies to translate genome editing to the clinic. Nat. Med. 23, 415\u2013423 (2017).","journal-title":"Nat. Med."},{"key":"51_CR63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2017.09.002","volume":"68","author":"KL Maxwell","year":"2017","unstructured":"Maxwell, K. L. The anti-CRISPR story: a battle for survival. Mol. Cell 68, 8\u201314 (2017).","journal-title":"Mol. Cell"},{"key":"51_CR64","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1093\/nar\/gku385","volume":"42","author":"A Fiszer","year":"2014","unstructured":"Fiszer, A. & Krzyzosiak, W. J. Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 42, 6787\u20136810 (2014).","journal-title":"Nucleic Acids Res."},{"key":"51_CR65","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser, M. S., Kordasiewicz, H. B. & McBride, J. L. Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia. Hum. Mol. Genet. 25, R53\u2013R64 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR66","doi-asserted-by":"crossref","first-page":"347ra94","DOI":"10.1126\/scitranslmed.aaf5660","volume":"8","author":"Y Miyazaki","year":"2016","unstructured":"Miyazaki, Y., Du, X., Muramatsu, S. & Gomez, C. M. An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron. Sci. Transl Med. 8, 347ra94 (2016).","journal-title":"Sci. Transl Med."},{"issue":"Suppl. 15","key":"51_CR67","doi-asserted-by":"crossref","first-page":"CT.002","DOI":"10.1212\/WNL.90.15_supplement.CT.002","volume":"90","author":"S Tabrizi","year":"2018","unstructured":"Tabrizi, S. et al. Effects of IONIS-HTTRx in patients with early Huntington\u2019s disease, results of the first HTT-lowering drug trial. Neurology 90 (Suppl. 15), CT.002 (2018).","journal-title":"Neurology"},{"key":"51_CR68","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1074\/jbc.R800041200","volume":"284","author":"HY Zoghbi","year":"2009","unstructured":"Zoghbi, H. Y. & Orr, H. T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 284, 7425\u20137429 (2009).","journal-title":"J. Biol. Chem."},{"key":"51_CR69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature12204","volume":"498","author":"J Park","year":"2013","unstructured":"Park, J. et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 498, 325\u2013331 (2013).","journal-title":"Nature"},{"key":"51_CR70","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/brain\/awv262","volume":"138","author":"A Teixeira-Castro","year":"2015","unstructured":"Teixeira-Castro, A. et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain 138, 3221\u20133237 (2015).","journal-title":"Brain"},{"key":"51_CR71","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/brain\/aww228","volume":"139","author":"MD Costa","year":"2016","unstructured":"Costa, M. D. et al. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain 139, 2891\u20132908 (2016).","journal-title":"Brain"},{"key":"51_CR72","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1007\/s12035-016-0120-z","volume":"54","author":"SD Reis","year":"2017","unstructured":"Reis, S. D., Pinho, B. R. & Oliveira, J. M. A. Modulation of molecular chaperones in Huntington\u2019s disease and other polyglutamine disorders. Mol.\u00a0Neurobiol. 54, 5829\u20135854 (2017).","journal-title":"Mol. Neurobiol."},{"key":"51_CR73","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuroscience.2016.03.064","volume":"327","author":"Y Ding","year":"2016","unstructured":"Ding, Y. et al. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1. Neuroscience 327, 20\u201331 (2016).","journal-title":"Neuroscience"},{"key":"51_CR74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003781","volume":"9","author":"M Cushman-Nick","year":"2013","unstructured":"Cushman-Nick, M., Bonini, N. M. & Shorter, J. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD\/SCA3 model. PLoS Genet. 9, e1003781 (2013).","journal-title":"PLoS Genet."},{"key":"51_CR75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/138920110790909650","volume":"11","author":"Y Nagai","year":"2011","unstructured":"Nagai, Y., Fujikake, N., Popiel, H. A. & Wada, K. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr. Pharm. Biotechnol. 11, 188\u2013197 (2011).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"51_CR76","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1093\/hmg\/ddv174","volume":"24","author":"WL Tsou","year":"2015","unstructured":"Tsou, W. L. et al. DnaJ-1 and karyopherin a3 suppress degeneration in a new Drosophila model of spinocerebellar ataxia Type 6. Hum. Mol. Genet. 24, 4385\u20134396 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR77","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.nbd.2008.10.016","volume":"33","author":"AJ Williams","year":"2009","unstructured":"Williams, A. J., Knutson, T. M., Colomer Gould, V. F. & Paulson, H. L. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol. Dis. 33, 342\u2013353 (2009).","journal-title":"Neurobiol. Dis."},{"key":"51_CR78","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00401-014-1289-8","volume":"128","author":"S Alves","year":"2014","unstructured":"Alves, S. et al. The autophagy\/lysosome pathway is impaired in SCA7 patients and SCA7 knock-in mice. Acta Neuropathol. 128, 705\u2013722 (2014).","journal-title":"Acta Neuropathol."},{"key":"51_CR79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature22078","volume":"545","author":"A Ashkenazi","year":"2017","unstructured":"Ashkenazi, A. et al. Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature 545, 108\u2013111 (2017).","journal-title":"Nature"},{"key":"51_CR80","doi-asserted-by":"crossref","DOI":"10.1038\/srep28220","volume":"6","author":"I Onofre","year":"2016","unstructured":"Onofre, I. et al. Fibroblasts of Machado Joseph disease patients reveal autophagy impairment. Sci. Rep. 6, 28220 (2016).","journal-title":"Sci. Rep."},{"key":"51_CR81","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.cub.2017.10.054","volume":"27","author":"O Baron","year":"2017","unstructured":"Baron, O. et al. Stall in canonical autophagy-lysosome pathways prompts nucleophagy-based nuclear breakdown in neurodegeneration. Curr. Biol. 27, 3626\u20133642 (2017).","journal-title":"Curr. Biol."},{"key":"51_CR82","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/brain\/awx081","volume":"140","author":"M Coutelier","year":"2017","unstructured":"Coutelier, M. et al. A panel study on patients with dominant cerebellar ataxia highlights the frequency of channelopathies. Brain 140, 1579\u20131594 (2017).","journal-title":"Brain"},{"key":"51_CR83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrneurol.2016.18","volume":"12","author":"JC Jen","year":"2016","unstructured":"Jen, J. C., Ashizawa, T., Griggs, R. C. & Waters, M. F. Rare neurological channelopathies \u2014 networks to study patients, pathogenesis and treatment. Nat. Rev. Neurol. 12, 195\u2013203 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"51_CR84","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","volume":"44","author":"CT Bever Jr","year":"1994","unstructured":"Bever, C. T. Jr et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054\u20131059 (1994).","journal-title":"Neurology"},{"key":"51_CR85","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman, A. D. et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373, 732\u2013738 (2009).","journal-title":"Lancet"},{"key":"51_CR86","doi-asserted-by":"crossref","first-page":"11795","DOI":"10.1523\/JNEUROSCI.0905-11.2011","volume":"31","author":"R Hourez","year":"2011","unstructured":"Hourez, R. et al. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 31, 11795\u201311807 (2011).","journal-title":"J. Neurosci."},{"key":"51_CR87","doi-asserted-by":"crossref","DOI":"10.1038\/srep29489","volume":"6","author":"S Jayabal","year":"2016","unstructured":"Jayabal, S., Chang, H. H., Cullen, K. E. & Watt, A. J. 4-Aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6. Sci. Rep. 6, 29489 (2016).","journal-title":"Sci. Rep."},{"key":"51_CR88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0022-510X(83)90008-4","volume":"61","author":"I Sobue","year":"1983","unstructured":"Sobue, I. et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J. Neurol. Sci. 61, 235\u2013248 (1983).","journal-title":"J. Neurol. Sci."},{"key":"51_CR89","first-page":"4169","volume":"13","author":"I Kanazawa","year":"1997","unstructured":"Kanazawa, I. et al. Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration: a multi-center double-blind comparative study with placebo. J. Clin. Ther. Med. 13, 4169\u20134224 (1997).","journal-title":"J. Clin. Ther. Med."},{"key":"51_CR90","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.neuron.2014.10.026","volume":"84","author":"R Ranganathan","year":"2014","unstructured":"Ranganathan, R. NINDS translational programs: priming the pump of neurotherapeutics discovery and development. Neuron 84, 515\u2013520 (2014).","journal-title":"Neuron"},{"key":"51_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.02.005","author":"DD Bushart","year":"2018","unstructured":"Bushart, D. D. & Shakkottai, V. G. Ion channel dysfunction in cerebellar ataxia. Neurosci. Lett. https:\/\/doi.org\/10.1016\/j.neulet.2018.02.005 (2018).","journal-title":"Neurosci. Lett."},{"key":"51_CR92","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.chembiol.2012.07.013","volume":"19","author":"AW Kasumu","year":"2012","unstructured":"Kasumu, A. W. et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem. Biol. 19, 1340\u20131353 (2012).","journal-title":"Chem. Biol."},{"key":"51_CR93","doi-asserted-by":"crossref","first-page":"15533","DOI":"10.1523\/JNEUROSCI.2454-12.2012","volume":"32","author":"Z Gao","year":"2012","unstructured":"Gao, Z. et al. Cerebellar ataxia by enhanced Ca(V)2.1 currents is alleviated by Ca2+-dependent K+-channel activators in Cacna1a(S218L) mutant mice. J. Neurosci. 32, 15533\u201315546 (2012).","journal-title":"J. Neurosci."},{"key":"51_CR94","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.celrep.2016.02.054","volume":"14","author":"G Grasselli","year":"2016","unstructured":"Grasselli, G. et al. Activity-dependent plasticity of spike pauses in cerebellar Purkinje cells. Cell Rep. 14, 2546\u20132553 (2016).","journal-title":"Cell Rep."},{"key":"51_CR95","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1113\/jphysiol.2011.205823","volume":"589","author":"E Hosy","year":"2011","unstructured":"Hosy, E., Piochon, C., Teuling, E., Rinaldo, L. & Hansel, C. SK2 channel expression and function in cerebellar Purkinje cells. J. Physiol. 589, 3433\u20133440 (2011).","journal-title":"J. Physiol."},{"key":"51_CR96","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1172\/JCI200420216","volume":"113","author":"VG Shakkottai","year":"2004","unstructured":"Shakkottai, V. G. et al. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J. Clin. Invest. 113, 582\u2013590 (2004).","journal-title":"J. Clin. Invest."},{"key":"51_CR97","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuron.2012.05.025","volume":"75","author":"G Ohtsuki","year":"2012","unstructured":"Ohtsuki, G., Piochon, C., Adelman, J. P. & Hansel, C. SK2 channel modulation contributes to compartment-specific dendritic plasticity in cerebellar Purkinje cells. Neuron 75, 108\u2013120 (2012).","journal-title":"Neuron"},{"key":"51_CR98","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1093\/hmg\/ddx281","volume":"26","author":"JM Dell\u2019Orco","year":"2017","unstructured":"Dell\u2019Orco, J. M., Pulst, S. M. & Shakkottai, V. G. Potassium channel dysfunction underlies Purkinje neuron spiking abnormalities in spinocerebellar ataxia type 2. Hum. Mol. Genet. 26, 3935\u20133945 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR99","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/acn3.527","volume":"5","author":"DD Bushart","year":"2018","unstructured":"Bushart, D. D. et al. Targeting potassium channels to treat cerebellar ataxia. Ann. Clin. Transl Neurol. 5, 297\u2013314 (2018).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"51_CR100","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1152\/jn.00913.2015","volume":"115","author":"PA Egorova","year":"2016","unstructured":"Egorova, P. A., Zakharova, O. A., Vlasova, O. L. & Bezprozvanny, I. B. In vivo analysis of cerebellar Purkinje cell activity in SCA2 transgenic mouse model. J. Neurophysiol. 115, 2840\u20132851 (2016).","journal-title":"J. Neurophysiol."},{"key":"51_CR101","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","volume":"74","author":"G Ristori","year":"2010","unstructured":"Ristori, G. et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74, 839\u2013845 (2010).","journal-title":"Neurology"},{"key":"51_CR102","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","volume":"14","author":"S Romano","year":"2015","unstructured":"Romano, S. et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985\u2013991 (2015).","journal-title":"Lancet Neurol."},{"key":"51_CR103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-0404.1995.tb00430.x","volume":"91","author":"M Leone","year":"1995","unstructured":"Leone, M., Bottacchi, E., D\u2019Alessandro, G. & Kustermann, S. Hereditary ataxias and paraplegias in Valle d\u2019Aosta, Italy: a study of prevalence and disability. Acta Neurol. Scand. 91, 183\u2013187 (1995).","journal-title":"Acta Neurol. Scand."},{"key":"51_CR104","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0895-4356(97)00202-3","volume":"50","author":"MC Silva","year":"1997","unstructured":"Silva, M. C., Coutinho, P., Pinheiro, C. D., Neves, J. M. & Serrano, P. Hereditary ataxias and spastic paraplegias: methodological aspects of a prevalence study in Portugal. J. Clin. Epidemiol. 50, 1377\u20131384 (1997).","journal-title":"J. Clin. Epidemiol."},{"key":"51_CR105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/WNL.58.5.702","volume":"58","author":"BP Warrenburg van de","year":"2002","unstructured":"van de Warrenburg, B. P. et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 58, 702\u2013708 (2002).","journal-title":"Neurology"},{"key":"51_CR106","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000358801","volume":"42","author":"L Ruano","year":"2014","unstructured":"Ruano, L., Melo, C., Silva, M. C. & Coutinho, P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 42, 174\u2013183 (2014).","journal-title":"Neuroepidemiology"},{"key":"51_CR107","unstructured":"NIH. Rare diseases clinical research network. nih.gov https:\/\/report.nih.gov\/nihfactsheets\/ViewFactSheet.aspx?csid=126 (2018)."},{"key":"51_CR108","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch, T. et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66, 1717\u20131720 (2006).","journal-title":"Neurology"},{"key":"51_CR109","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-177","volume":"8","author":"T Ashizawa","year":"2013","unstructured":"Ashizawa, T. et al. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J. Rare Dis. 8, 177 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"51_CR110","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","volume":"14","author":"H Jacobi","year":"2015","unstructured":"Jacobi, H. et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 14, 1101\u20131108 (2015).","journal-title":"Lancet Neurol."},{"key":"51_CR111","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1474-4422(13)70104-2","volume":"12","author":"H Jacobi","year":"2013","unstructured":"Jacobi, H. et al. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol. 12, 650\u2013658 (2013).","journal-title":"Lancet Neurol."},{"key":"51_CR112","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12311-011-0292-z","volume":"11","author":"H Jacobi","year":"2012","unstructured":"Jacobi, H. et al. Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings. Cerebellum 11, 155\u2013166 (2012).","journal-title":"Cerebellum"},{"key":"51_CR113","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2015.08.019","volume":"358","author":"JA Saute","year":"2015","unstructured":"Saute, J. A. et al. Planning future clinical trials in Machado Joseph disease: lessons from a phase 2 trial. J. Neurol. Sci. 358, 72\u201376 (2015).","journal-title":"J. Neurol. Sci."},{"key":"51_CR114","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1212\/WNL.0000000000001711","volume":"85","author":"RP Maas","year":"2015","unstructured":"Maas, R. P., van Gaalen, J., Klockgether, T. & van de Warrenburg, B. P. The preclinical stage of spinocerebellar ataxias. Neurology 85, 96\u2013103 (2015).","journal-title":"Neurology"},{"key":"51_CR115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/bies.201600048","volume":"38","author":"DC Rubinsztein","year":"2016","unstructured":"Rubinsztein, D. C. & Orr, H. T. Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: there may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile. Bioessays 38, 977\u2013980 (2016).","journal-title":"Bioessays"},{"key":"51_CR116","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-510X(96)00231-6","volume":"145","author":"P Trouillas","year":"1997","unstructured":"Trouillas, P. et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J. Neurol. Sci. 145, 205\u2013211 (1997).","journal-title":"J. Neurol. Sci."},{"key":"51_CR117","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.neuroscience.2009.06.023","volume":"162","author":"JD Schmahmann","year":"2009","unstructured":"Schmahmann, J. D., Macmore, J. & Vangel, M. Cerebellar stroke without motor deficit: clinical evidence for motor and non-motor domains within the human cerebellum. Neuroscience 162, 852\u2013861 (2009).","journal-title":"Neuroscience"},{"key":"51_CR118","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/mds.22681","volume":"24","author":"JD Schmahmann","year":"2009","unstructured":"Schmahmann, J. D., Gardner, R., MacMore, J. & Vangel, M. G. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov. Disord. 24, 1820\u20131828 (2009).","journal-title":"Mov. Disord."},{"key":"51_CR119","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1468-1331.2008.02078.x","volume":"15","author":"C Kieling","year":"2008","unstructured":"Kieling, C. et al. A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). Eur. J. Neurol. 15, 371\u2013376 (2008).","journal-title":"Eur. J. Neurol."},{"key":"51_CR120","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12311-011-0316-8","volume":"11","author":"JA Saute","year":"2012","unstructured":"Saute, J. A. et al. Ataxia rating scales\u2014psychometric profiles, natural history and their application in clinical trials. Cerebellum 11, 488\u2013504 (2012).","journal-title":"Cerebellum"},{"key":"51_CR121","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s12311-017-0855-8","volume":"16","author":"TL Monte","year":"2017","unstructured":"Monte, T. L. et al. NESSCA validation and responsiveness of several rating scales in spinocerebellar ataxia type 2. Cerebellum 16, 852\u2013858 (2017).","journal-title":"Cerebellum"},{"key":"51_CR122","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/brain\/awn059","volume":"131","author":"ST Montcel du","year":"2008","unstructured":"du Montcel, S. T. et al. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain 131, 1352\u20131361 (2008).","journal-title":"Brain"},{"key":"51_CR123","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1212\/01.wnl.0000324863.76290.19","volume":"71","author":"T Schmitz-Hubsch","year":"2008","unstructured":"Schmitz-Hubsch, T. et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71, 486\u2013492 (2008).","journal-title":"Neurology"},{"key":"51_CR124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12311-016-0760-6","volume":"16","author":"G Chini","year":"2017","unstructured":"Chini, G. et al. Local stability of the trunk in patients with degenerative cerebellar ataxia during walking. Cerebellum 16, 26\u201333 (2017).","journal-title":"Cerebellum"},{"key":"51_CR125","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.0b013e3181d1a6c9","volume":"74","author":"T Schmitz-H\u00fcbsch","year":"2010","unstructured":"Schmitz-H\u00fcbsch, T. et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 74, 678\u2013684 (2010).","journal-title":"Neurology"},{"key":"51_CR126","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/mds.23531","volume":"26","author":"E Chan","year":"2011","unstructured":"Chan, E. et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov. Disord. 26, 534\u2013538 (2011).","journal-title":"Mov. Disord."},{"key":"51_CR127","doi-asserted-by":"crossref","first-page":"N105","DOI":"10.1088\/0967-3334\/37\/11\/N105","volume":"37","author":"A Hickey","year":"2016","unstructured":"Hickey, A. et al. Validity of a wearable accelerometer to quantify gait in spinocerebellar ataxia type 6. Physiol. Meas. 37, N105\u2013N117 (2016).","journal-title":"Physiol. Meas."},{"key":"51_CR128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jns.2011.09.016","volume":"313","author":"SH Subramony","year":"2012","unstructured":"Subramony, S. H. et al. Objective home-based gait assessment in spinocerebellar ataxia. J. Neurol. Sci. 313, 95\u201398 (2012).","journal-title":"J. Neurol. Sci."},{"key":"51_CR129","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/brain\/awu174","volume":"137","author":"S Tezenas du Montcel","year":"2014","unstructured":"Tezenas du Montcel, S. et al. Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain 137, 2444\u20132455 (2014).","journal-title":"Brain"},{"key":"51_CR130","volume":"139","author":"Z Chen","year":"2016","unstructured":"Chen, Z. et al. (CAG)n loci as genetic modifiers of age-at-onset in patients with Machado-Joseph disease from mainland China. Brain 139, e41 (2016).","journal-title":"Brain"},{"key":"51_CR131","volume":"10","author":"Z Long","year":"2015","unstructured":"Long, Z. et al. Two novel SNPs in ATXN3 3\u2032UTR may decrease age at onset of SCA3\/MJD in Chinese patients. PLoS ONE 10, e0117488 (2015).","journal-title":"PLoS ONE"},{"key":"51_CR132","doi-asserted-by":"crossref","first-page":"2179e15","DOI":"10.1016\/j.neurobiolaging.2014.03.020","volume":"35","author":"H Peng","year":"2014","unstructured":"Peng, H. et al. APOE epsilon2 allele may decrease the\u00a0age at onset in patients with spinocerebellar ataxia type 3 or Machado-Joseph disease from the Chinese Han population. Neurobiol. Aging 35, 2179e15\u20132179e18 (2014).","journal-title":"Neurobiol. Aging"},{"key":"51_CR133","volume":"10","author":"C Wang","year":"2015","unstructured":"Wang, C. et al. Analysis of the GGGGCC repeat expansions of the C9orf72 gene in SCA3\/MJD patients from China. PLoS ONE 10, e0130336 (2015).","journal-title":"PLoS ONE"},{"key":"51_CR134","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12017-016-8416-8","volume":"19","author":"M Raposo","year":"2017","unstructured":"Raposo, M. et al. Promoter variation and expression levels of inflammatory genes IL1A, IL1B, IL6 and TNF in blood of spinocerebellar ataxia type 3 (SCA3) patients. Neuromol. Med. 19, 41\u201345 (2017).","journal-title":"Neuromol. Med."},{"key":"51_CR135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archneurol.2011.2713","volume":"69","author":"S Tezenas du Montcel","year":"2012","unstructured":"Tezenas du Montcel, S. et al. Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia. Arch. Neurol. 69, 500\u2013508 (2012).","journal-title":"Arch. Neurol."},{"key":"51_CR136","volume":"9","author":"Q Zhou","year":"2014","unstructured":"Zhou, Q. et al. The role of apolipoprotein E as a risk factor for an earlier age at onset for Machado-Joseph disease is doubtful. PLoS ONE 9, e111356 (2014).","journal-title":"PLoS ONE"},{"key":"51_CR137","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12311-013-0510-y","volume":"13","author":"RM Castilhos de","year":"2014","unstructured":"de Castilhos, R. M. et al. Spinocerebellar ataxias in Brazil\u2014frequencies and modulating effects of related genes. Cerebellum 13, 17\u201328 (2014).","journal-title":"Cerebellum"},{"key":"51_CR138","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89\u201395 (2001).","journal-title":"Clin. Pharmacol. Ther."},{"key":"51_CR139","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/nbm.1062","volume":"19","author":"SG Mueller","year":"2006","unstructured":"Mueller, S. G., Schuff, N. & Weiner, M. W. Evaluation of treatment effects in Alzheimer\u2019s and other neurodegenerative diseases by MRI and MRS. NMR Biomed. 19, 655\u2013668 (2006).","journal-title":"NMR Biomed."},{"key":"51_CR140","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/brain\/aws369","volume":"136","author":"K Reetz","year":"2013","unstructured":"Reetz, K. et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain 136, 905\u201391711 (2013).","journal-title":"Brain"},{"key":"51_CR141","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12311-012-0405-3","volume":"12","author":"S Currie","year":"2013","unstructured":"Currie, S. et al. Magnetic resonance imaging biomarkers in patients with progressive ataxia: current status and future direction. Cerebellum 12, 245\u2013266 (2013).","journal-title":"Cerebellum"},{"key":"51_CR142","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00429-016-1263-4","volume":"222","author":"N Kang","year":"2017","unstructured":"Kang, N. et al. Sensory and motor cortex function contributes to symptom severity in spinocerebellar ataxia type 6. Brain Struct. Funct. 222, 1039\u20131052 (2017).","journal-title":"Brain Struct. Funct."},{"key":"51_CR143","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1002\/hbm.23266","volume":"37","author":"JV Duarte","year":"2016","unstructured":"Duarte, J. V. et al. Parametric fMRI of paced motor responses uncovers novel whole-brain imaging biomarkers in spinocerebellar ataxia type 3. Hum.\u00a0Brain Mapp. 37, 3656\u20133668 (2016).","journal-title":"Hum. Brain Mapp."},{"key":"51_CR144","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/brain\/121.9.1687","volume":"121","author":"T Klockgether","year":"1998","unstructured":"Klockgether, T. et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 121, 1687\u20131693 (1998).","journal-title":"Brain"},{"key":"51_CR145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neuroimage.2009.07.027","volume":"49","author":"JB Schulz","year":"2010","unstructured":"Schulz, J. B. et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage 49, 158\u2013168 (2010).","journal-title":"Neuroimage"},{"key":"51_CR146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuroimage.2008.06.036","volume":"43","author":"R Nave Della","year":"2008","unstructured":"Della Nave, R. et al. Brain white matter damage in SCA1 and SCA2. An in vivo study using voxel-based morphometry, histogram analysis of mean diffusivity and tract-based spatial statistics. Neuroimage 43, 10\u201319 (2008).","journal-title":"Neuroimage"},{"key":"51_CR147","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.3174\/ajnr.A0716","volume":"28","author":"ML Mandelli","year":"2007","unstructured":"Mandelli, M. L. et al. Diffusion tensor imaging of spinocerebellar ataxias types 1 and 2. Am. J. Neuroradiol. 28, 1996\u20132000 (2007).","journal-title":"Am. J. Neuroradiol."},{"issue":"Suppl. 2","key":"51_CR148","doi-asserted-by":"crossref","first-page":"T72","DOI":"10.1016\/j.neuroimage.2009.05.013","volume":"47","author":"N Prakash","year":"2009","unstructured":"Prakash, N. et al. Patterns of fractional anisotropy changes in white matter of cerebellar peduncles distinguish spinocerebellar ataxia-1 from multiple system atrophy and other ataxia syndromes. Neuroimage 47 (Suppl. 2), T72\u2013T81 (2009).","journal-title":"Neuroimage"},{"key":"51_CR149","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/mds.25451","volume":"28","author":"RP Guimaraes","year":"2013","unstructured":"Guimaraes, R. P. et al. A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3. Mov. Disord. 28, 1125\u20131132 (2013).","journal-title":"Mov. Disord."},{"key":"51_CR150","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12311-010-0214-5","volume":"10","author":"A Solodkin","year":"2011","unstructured":"Solodkin, A., Peri, E., Chen, E. E., Ben-Jacob, E. & Gomez, C. M. Loss of intrinsic organization of cerebellar networks in spinocerebellar ataxia type 1: correlates with disease severity and duration. Cerebellum 10, 218\u2013232 (2011).","journal-title":"Cerebellum"},{"key":"51_CR151","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1093\/cercor\/bhv154","volume":"26","author":"MI Falcon","year":"2016","unstructured":"Falcon, M. I., Gomez, C. M., Chen, E. E., Shereen, A. & Solodkin, A. Early cerebellar network shifting in spinocerebellar ataxia type 6. Cereb. Cortex 26, 3205\u20133218 (2016).","journal-title":"Cereb. Cortex"},{"key":"51_CR152","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3174\/ajnr.A4343","volume":"36","author":"M Mascalchi","year":"2015","unstructured":"Mascalchi, M. et al. Progression of microstructural damage in spinocerebellar ataxia type 2: a longitudinal DTI study. Am. J. Neuroradiol 36, 1096\u20131101 (2015).","journal-title":"Am. J. Neuroradiol"},{"key":"51_CR153","first-page":"239","volume":"31","author":"M Dayan","year":"2016","unstructured":"Dayan, M. et al. Impact of cerebellar atrophy on cortical gray matter and cerebellar peduncles as assessed by voxel-based morphometry and high angular resolution diffusion imaging. Funct. Neurol. 31, 239\u2013248 (2016).","journal-title":"Funct. Neurol."},{"key":"51_CR154","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jocn.2014.08.006","volume":"22","author":"MN Rozenfeld","year":"2015","unstructured":"Rozenfeld, M. N. et al. An investigation of diffusion imaging techniques in the evaluation of spinocerebellar ataxia and multisystem atrophy. J. Clin. Neurosci. 22, 166\u2013172 (2015).","journal-title":"J. Clin. Neurosci."},{"key":"51_CR155","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1148\/radiol.13130531","volume":"270","author":"G \u00d6z","year":"2014","unstructured":"\u00d6z, G. et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 270, 658\u2013679 (2014).","journal-title":"Radiology"},{"key":"51_CR156","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.parkreldis.2004.02.006","volume":"10","author":"M Viau","year":"2004","unstructured":"Viau, M. & Boulanger, Y. Characterization of ataxias with magnetic resonance imaging and spectroscopy. Parkinsonism Relat. Disord. 10, 335\u2013351 (2004).","journal-title":"Parkinsonism Relat. Disord."},{"key":"51_CR157","volume-title":"Handbook of the Cerebellum and Cerebellar Disorders","author":"G \u00d6z","year":"2013","unstructured":"\u00d6z, G. in Handbook of the Cerebellum and Cerebellar Disorders (eds Manto, M., Gruol, D. L., Schmahman, J. D., Koibuchi, N. & Rossi, F.) (Springer, Dordrecht, 2013)."},{"key":"51_CR158","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ana.25212","volume":"83","author":"JM Joers","year":"2018","unstructured":"Joers, J. M. et al. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann. Neurol. 83, 816\u2013829 (2018).","journal-title":"Ann. Neurol."},{"key":"51_CR159","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/mds.23067","volume":"25","author":"G \u00d6z","year":"2010","unstructured":"\u00d6z, G. et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov. Disord. 25, 1253\u20131261 (2010).","journal-title":"Mov. Disord."},{"key":"51_CR160","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12311-010-0213-6","volume":"10","author":"G \u00d6z","year":"2011","unstructured":"\u00d6z, G. et al. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum 10, 208\u2013217 (2011).","journal-title":"Cerebellum"},{"key":"51_CR161","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mds.26181","volume":"30","author":"IM Adanyeguh","year":"2015","unstructured":"Adanyeguh, I. M. et al. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov. Disord. 30, 662\u2013670 (2015).","journal-title":"Mov. Disord."},{"key":"51_CR162","first-page":"64","volume":"22","author":"DK Deelchand","year":"2014","unstructured":"Deelchand, D. K. et al. High field MRS is more sensitive to progression of neurodegeneration than clinical decline in spinocerebellar ataxia type 1 (SCA1). Proc. Int. Soc. Magn. Reson. Med. 22, 64 (2014).","journal-title":"Proc. Int. Soc. Magn. Reson. Med."},{"key":"51_CR163","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1523\/JNEUROSCI.5612-09.2010","volume":"30","author":"G \u00d6z","year":"2010","unstructured":"\u00d6z, G. et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 30, 3831\u20133838 (2010).","journal-title":"J. Neurosci."},{"key":"51_CR164","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.expneurol.2011.09.021","volume":"232","author":"G \u00d6z","year":"2011","unstructured":"\u00d6z, G. et al. In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp. Neurol. 232, 290\u2013298 (2011).","journal-title":"Exp. Neurol."},{"key":"51_CR165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.nbd.2014.11.011","volume":"74","author":"G \u00d6z","year":"2015","unstructured":"\u00d6z, G. et al. Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: Comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology. Neurobiol. Dis. 74, 158\u2013166 (2015).","journal-title":"Neurobiol. Dis."},{"key":"51_CR166","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/jnc.12435","volume":"127","author":"UE Emir","year":"2013","unstructured":"Emir, U. E., Brent Clark, H., Vollmers, M. L., Eberly, L. E. & \u00d6z, G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J. Neurochem. 127, 660\u2013668 (2013).","journal-title":"J. Neurochem."},{"key":"51_CR167","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mrm.26022","volume":"76","author":"M Terpstra","year":"2016","unstructured":"Terpstra, M. et al. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. Magn. Reson. Med. 76, 1083\u20131091 (2016).","journal-title":"Magn. Reson. Med."},{"key":"51_CR168","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/mrm.25295","volume":"73","author":"DK Deelchand","year":"2015","unstructured":"Deelchand, D. K. et al. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T. Magn. Reson. Med. 73, 1718\u20131725 (2015).","journal-title":"Magn. Reson. Med."},{"key":"51_CR169","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/nbm.3252","volume":"28","author":"BL Bank van de","year":"2015","unstructured":"van de Bank, B. L. et al. Multi-center reproducibility of neurochemical profiles in the human brain at 7\u2005T. NMR Biomed. 28, 306\u2013316 (2015).","journal-title":"NMR Biomed."},{"key":"51_CR170","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/ana.410430215","volume":"43","author":"M Mascalchi","year":"1998","unstructured":"Mascalchi, M. et al. Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1. Ann. Neurol. 43, 244\u2013252 (1998).","journal-title":"Ann. Neurol."},{"key":"51_CR171","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10072-005-0438-1","volume":"26","author":"M Ragno","year":"2005","unstructured":"Ragno, M. et al. Multimodal electrophysiologic follow-up study in 3 mutated but presymptomatic members of a spinocerebellar ataxia type 1 (SCA1) family. Neurol. Sci. 26, 67\u201371 (2005).","journal-title":"Neurol. Sci."},{"key":"51_CR172","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2016.12.031","volume":"36","author":"YJ Yoo","year":"2017","unstructured":"Yoo, Y. J. & Oh, J. Identification of early neurodegenerative change in presymptomatic spinocerebellar ataxia type 1: a diffusion tensor imaging study. Parkinsonism Relat. Disord. 36, 109\u2013110 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"51_CR173","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1552-6569.2011.00614.x","volume":"22","author":"A D\u2019Abreu","year":"2012","unstructured":"D\u2019Abreu, A. et al. Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study. J. Neuroimag. 22, 285\u2013291 (2012).","journal-title":"J. Neuroimag."},{"key":"51_CR174","doi-asserted-by":"crossref","first-page":"413098","DOI":"10.1155\/2015\/413098","volume":"2015","author":"AM Brouillette","year":"2015","unstructured":"Brouillette, A. M., \u00d6z, G. & Gomez, C. M. Cerebrospinal fluid biomarkers in spinocerebellar ataxia: a pilot study. Dis. Markers 2015, 413098 (2015).","journal-title":"Dis. Markers"},{"key":"51_CR175","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fneur.2017.00485","volume":"8","author":"AM Assis de","year":"2017","unstructured":"de Assis, A. M. et al. Peripheral oxidative stress biomarkers in spinocerebellar ataxia type 3\/Machado-Joseph disease. Front. Neurol. 8, 485 (2017).","journal-title":"Front. Neurol."},{"key":"51_CR176","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12311-015-0719-z","volume":"15","author":"G Silva Carvalho da","year":"2016","unstructured":"da Silva Carvalho, G. et al. Cytokines in Machado Joseph disease\/spinocerebellar ataxia 3. Cerebellum 15, 518\u2013525 (2016).","journal-title":"Cerebellum"},{"key":"51_CR177","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2014.03.045","volume":"341","author":"D Almaguer-Gotay","year":"2014","unstructured":"Almaguer-Gotay, D. et al. Role of glutathione S-transferases in the spinocerebellar ataxia type 2 clinical phenotype. J. Neurol. Sci. 341, 41\u201345 (2014).","journal-title":"J. Neurol. Sci."},{"key":"51_CR178","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/dna.2010.1165","volume":"30","author":"V Swarup","year":"2011","unstructured":"Swarup, V., Srivastava, A. K., Padma, M. V. & Rajeswari, M. R. Quantification of circulating plasma DNA in Friedreich\u2019s ataxia and spinocerebellar ataxia types 2 and 12. DNA Cell Biol. 30, 389\u2013394 (2011).","journal-title":"DNA Cell Biol."},{"key":"51_CR179","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.arcmed.2017.06.008","volume":"48","author":"DA Cuello-Almarales","year":"2017","unstructured":"Cuello-Almarales, D. A. et al. Buccal cell micronucleus frequency is significantly elevated in patients with spinocerebellar ataxia type 2. Arch. Med. Res. 48, 297\u2013302 (2017).","journal-title":"Arch. Med. Res."},{"key":"51_CR180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/01658107.2011.580898","volume":"35","author":"JH Pula","year":"2011","unstructured":"Pula, J. H. et al. Retinal nerve fibre layer and macular thinning in spinocerebellar ataxia and cerebellar multisystem atrophy. Neuroophthalmology 35, 108\u2013114 (2011).","journal-title":"Neuroophthalmology"},{"key":"51_CR181","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/eye.2013.201","volume":"27","author":"G Alvarez","year":"2013","unstructured":"Alvarez, G. et al. Optical coherence tomography findings in spinocerebellar ataxia-3. Eye 27, 1376\u20131381 (2013).","journal-title":"Eye"},{"key":"51_CR182","volume":"7","author":"MTN Panouilleres","year":"2017","unstructured":"Panouilleres, M. T. N. et al. Sensorimotor adaptation as a behavioural biomarker of early spinocerebellar ataxia type 6. Sci. Rep. 7, 2366 (2017).","journal-title":"Sci. Rep."},{"key":"51_CR183","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1196\/annals.1325.059","volume":"1039","author":"C Seifried","year":"2005","unstructured":"Seifried, C. et al. Saccade velocity as a surrogate disease marker in spinocerebellar ataxia type 2. Ann.\u00a0NY Acad. Sci. 1039, 524\u2013527 (2005).","journal-title":"Ann. NY Acad. Sci."},{"key":"51_CR184","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/cns.12676","volume":"23","author":"C Wu","year":"2017","unstructured":"Wu, C. et al. Oculomotor deficits in spinocerebellar ataxia type 3: potential biomarkers of preclinical detection and disease progression. CNS Neurosci. Ther. 23, 321\u2013328 (2017).","journal-title":"CNS Neurosci. Ther."},{"key":"51_CR185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.03.033","volume":"306","author":"R Rodriguez-Labrada","year":"2011","unstructured":"Rodriguez-Labrada, R. et al. Saccadic latency is prolonged in spinocerebellar ataxia type 2 and correlates with the frontal-executive dysfunctions. J. Neurol. Sci. 306, 103\u2013107 (2011).","journal-title":"J. Neurol. Sci."},{"key":"51_CR186","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bandc.2014.07.007","volume":"91","author":"R Rodriguez-Labrada","year":"2014","unstructured":"Rodriguez-Labrada, R. et al. Executive deficit in spinocerebellar ataxia type 2 is related to expanded CAG repeats: evidence from antisaccadic eye movements. Brain Cogn. 91, 28\u201334 (2014).","journal-title":"Brain Cogn."},{"key":"51_CR187","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mds.26532","volume":"31","author":"R Rodriguez-Labrada","year":"2016","unstructured":"Rodriguez-Labrada, R. et al. Spinocerebellar ataxia type 2: measures of saccade changes improve power for clinical trials. Mov. Disord. 31, 570\u2013578 (2016).","journal-title":"Mov. Disord."},{"key":"51_CR188","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/WNO.0b013e318183bf5a","volume":"28","author":"CB Colen","year":"2008","unstructured":"Colen, C. B., Ketko, A., George, E. & Van Stavern, G. P. Periodic alternating nystagmus and periodic alternating skew deviation in spinocerebellar ataxia type 6. J. Neuroophthalmol. 28, 287\u2013288 (2008).","journal-title":"J. Neuroophthalmol."},{"key":"51_CR189","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/mds.23409","volume":"26","author":"R Rodriguez-Labrada","year":"2011","unstructured":"Rodriguez-Labrada, R. et al. Subtle rapid eye movement sleep abnormalities in presymptomatic spinocerebellar ataxia type 2 gene carriers. Mov. Disord. 26, 347\u2013350 (2011).","journal-title":"Mov. Disord."},{"key":"51_CR190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000324374","volume":"8","author":"L Velazquez-Perez","year":"2011","unstructured":"Velazquez-Perez, L. et al. Sleep disorders in spinocerebellar ataxia type 2 patients. Neurodegener. Dis. 8, 447\u2013454 (2011).","journal-title":"Neurodegener. Dis."},{"key":"51_CR191","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jns.2009.12.007","volume":"290","author":"D Dang","year":"2010","unstructured":"Dang, D. & Cunnington, D. Excessive daytime somnolence in spinocerebellar ataxia type 1. J. Neurol. Sci. 290, 146\u2013147 (2010).","journal-title":"J. Neurol. Sci."},{"key":"51_CR192","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2009.12.013","volume":"290","author":"L Velazquez-Perez","year":"2010","unstructured":"Velazquez-Perez, L. et al. Progression markers of Spinocerebellar ataxia 2. A twenty years neurophysiological follow up study. J. Neurol. Sci. 290, 22\u201326 (2010).","journal-title":"J. Neurol. Sci."},{"key":"51_CR193","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005398","volume":"4","author":"L Velazquez-Perez","year":"2009","unstructured":"Velazquez-Perez, L. et al. Motor decline in clinically presymptomatic spinocerebellar ataxia type 2 gene carriers. PLoS ONE 4, e5398 (2009).","journal-title":"PLoS ONE"},{"key":"51_CR194","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/mds.26835","volume":"31","author":"W Ilg","year":"2016","unstructured":"Ilg, W. et al. Individual changes in preclinical spinocerebellar ataxia identified via increased motor complexity. Mov Disord. 31, 1891\u20131900 (2016).","journal-title":"Mov Disord."},{"key":"51_CR195","unstructured":"Dominguez, C. Imaging mutant huntingtin aggregates: development of potential PET ligands. Oral Presentation, 253rd ACS National Meeting & Exposition, San Francisco, CA, United States, 2\u20136 April 2017, MEDI-320 (2017)."},{"key":"51_CR196","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","volume":"10","author":"H Xia","year":"2004","unstructured":"Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816\u2013820 (2004).","journal-title":"Nat. Med."},{"key":"51_CR197","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","volume":"22","author":"MS Keiser","year":"2014","unstructured":"Keiser, M. S., Boudreau, R. L. & Davidson, B. L. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol. Ther. 22, 588\u2013595 (2014).","journal-title":"Mol. Ther."},{"key":"51_CR198","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ana.24789","volume":"80","author":"MS Keiser","year":"2016","unstructured":"Keiser, M. S., Monteys, A. M., Corbau, R., Gonzalez-Alegre, P. & Davidson, B. L. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1. Ann. Neurol. 80, 754\u2013765 (2016).","journal-title":"Ann. Neurol."},{"key":"51_CR199","unstructured":"National Institute of Neurological Disorders and Stroke. CREATE-Bio program overview. NINDS https:\/\/www.ninds.nih.gov\/Current-Research\/Research-Funded-NINDS\/Translational-Research\/CREATE-BIO (2014)."},{"key":"51_CR200","unstructured":"National Institute of Neurological Disorders and Stroke. CREATE-Bio examples: milestones. NINDS https:\/\/www.ninds.nih.gov\/Funding\/Apply-Funding\/Application-Support-Library\/CREATE-Bio-Examples-Milestones (2014)."},{"key":"51_CR201","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1523\/JNEUROSCI.0660-09.2009","volume":"29","author":"J Liu","year":"2009","unstructured":"Liu, J. et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J. Neurosci. 29, 9148\u20139162 (2009).","journal-title":"J. Neurosci."},{"key":"51_CR202","doi-asserted-by":"crossref","first-page":"12713","DOI":"10.1523\/JNEUROSCI.3909-08.2008","volume":"28","author":"X Chen","year":"2008","unstructured":"Chen, X. et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 28, 12713\u201312724 (2008).","journal-title":"J. Neurosci."},{"key":"51_CR203","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003341","volume":"3","author":"S Alves","year":"2008","unstructured":"Alves, S. et al. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS ONE 3, e3341 (2008).","journal-title":"PLoS ONE"},{"key":"51_CR204","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/hmg\/ddq111","volume":"19","author":"S Alves","year":"2010","unstructured":"Alves, S. et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum. Mol. Genet. 19, 2380\u20132394 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"51_CR205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100086","volume":"9","author":"C N\u00f3brega","year":"2014","unstructured":"N\u00f3brega, C. et al. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease. PLoS ONE 9, e100086 (2014).","journal-title":"PLoS ONE"},{"key":"51_CR206","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/mt.2013.152","volume":"21","author":"E Rodriguez-Lebron","year":"2013","unstructured":"Rodriguez-Lebron, E. et al. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol. Ther. 21, 1909\u20131918 (2013).","journal-title":"Mol. Ther."},{"key":"51_CR207","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/mt.2013.144","volume":"21","author":"C Costa Mdo","year":"2013","unstructured":"Costa Mdo, C. et al. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol.\u00a0Ther. 21, 1898\u20131908 (2013).","journal-title":"Mol. Ther."},{"key":"51_CR208","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","volume":"544","author":"DR Scoles","year":"2017","unstructured":"Scoles, D. R. et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544, 362\u2013366 (2017).","journal-title":"Nature"},{"key":"51_CR209","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","volume":"7","author":"LR Moore","year":"2017","unstructured":"Moore, L. R. et al. Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models. Mol. Ther. Nucleic Acids 7, 200\u2013210 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"51_CR210","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","volume":"8","author":"LJA Toonen","year":"2017","unstructured":"Toonen, L. J. A., Rigo, F., van Attikum, H. & van Roon-Mom, W. M. C. Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol. Ther. Nucleic Acids 8, 232\u2013242 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"51_CR211","volume":"9","author":"PS Ramachandran","year":"2014","unstructured":"Ramachandran, P. S. et al. RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. PLOS One 9, e95362 (2014).","journal-title":"PLOS One"},{"key":"51_CR212","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/mt.2014.108","volume":"22","author":"PS Ramachandran","year":"2014","unstructured":"Ramachandran, P. S., Boudreau, R. L., Schaefer, K. A., La Spada, A. R. & Davidson, B. L. Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Mol. Ther. 22, 1635\u20131642 (2014).","journal-title":"Mol. Ther."},{"key":"51_CR213","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0b013e318225ab07","volume":"77","author":"M Strupp","year":"2011","unstructured":"Strupp, M. et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77, 269\u2013275 (2011).","journal-title":"Neurology"},{"key":"51_CR214","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00415-013-7029-5","volume":"260","author":"I Giordano","year":"2013","unstructured":"Giordano, I. et al. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia. J. Neurol. 260, 2175\u20132176 (2013).","journal-title":"J. Neurol."},{"key":"51_CR215","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01811706 (2015)"},{"key":"51_CR216","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1523\/JNEUROSCI.3953-15.2016","volume":"36","author":"EM Power","year":"2016","unstructured":"Power, E. M., Morales, A. & Empson, R. M. Prolonged type 1 metabotropic glutamate receptor dependent synaptic signaling contributes to spino-cerebellar ataxia type 1. J. Neurosci. 36, 4910\u20134916 (2016).","journal-title":"J. Neurosci."},{"key":"51_CR217","doi-asserted-by":"crossref","DOI":"10.1186\/1756-6606-6-48","volume":"6","author":"S Notartomaso","year":"2013","unstructured":"Notartomaso, S. et al. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol. Brain 6, 48 (2013).","journal-title":"Mol. Brain"},{"key":"51_CR218","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajhg.2017.08.005","volume":"101","author":"LM Watson","year":"2017","unstructured":"Watson, L. M. et al. Dominant mutations in GRM1 cause spinocerebellar ataxia type 44. Am. J. Hum. Genet. 101, 451\u2013458 (2017).","journal-title":"Am. J. Hum. Genet."}],"updated-by":[{"DOI":"10.1038\/s41582-018-0102-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000}}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-018-0051-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-018-0051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-018-0051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:14:38Z","timestamp":1720512878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-018-0051-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":218,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1038\/s41582-018-0051-6","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"21 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In Table 3 of this article as originally published, a sentence within the column \u201cComments\u201d in the row \u201cSCA6\u201d contains an error. The text incorrectly reads \u201cNeeds rigorous preclinical studies in SCA3 animal models\u201d. This sentence has been corrected to \u201cNeeds rigorous preclinical studies in SCA6 animal models\u201d in the PDF and HTML versions of the article.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A. has received honoraria and travel support from Pacific Biosciences. G.\u00d6. has received funding from Takeda Pharmaceuticals for a spinocerebellar ataxia (SCA) preclinical trial. H.L.P. recently completed a research contract with Ionis Pharmaceuticals for ASO treatments of\u00a0SCA3.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}